Cas:1245917-55-8 tert-butyl 3,5-dioxo-2,9-diazaspiro[5.5]undecane-9-carboxylate manufacturer & supplier

We serve Chemical Name:tert-butyl 3,5-dioxo-2,9-diazaspiro[5.5]undecane-9-carboxylate CAS:1245917-55-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

tert-butyl 3,5-dioxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

Chemical Name:tert-butyl 3,5-dioxo-2,9-diazaspiro[5.5]undecane-9-carboxylate
CAS.NO:1245917-55-8
Synonyms:9-boc-3,5-dioxo-2,9-diazaspiro[5.5]undecane;tert-butyl 9,11-dioxo-3,8-diazaspiro[5.5]undecane-3-carboxylate;c-8914
Molecular Formula:C14H22N2O4
Molecular Weight:282.33500
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.20000
Exact Mass:282.15800
LogP:1.30650

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 9-boc-3,5-dioxo-2,9-diazaspiro[5.5]undecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,c-8914 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 9,11-dioxo-3,8-diazaspiro[5.5]undecane-3-carboxylate Use and application,c-8914 technical grade,usp/ep/jp grade.


Related News: The group, after examining Soliris’ late-stage trial data, determined they’re highly certain it produces a small benefit to patients who are positive for anti-AChR antibodies, while there’s a “moderate certainty of a small or substantial net health benefit.” (E)-2-(2-(methylsulfonyl)vinyl)pyridine manufacturers In our phase 2 program, with partners BStrong, The Grant Cardone Foundation (https://grantcardonefoundation.com) and The Alexander Team (https://thealexanderteam.com), we supplied short term condo apartment units for 1-6 months underwritten by local hoteliers. 2,6-Dimethyl-2-pent-4-enyl-hept-6-enenitrile suppliers Alexion has been working to push Ultomiris through additional indications ahead of Soliris’ expected loss of exclusivity in 2025. 2-(4-aminophenyl)aniline vendor & factory.